Abstracts Archive - Page 221 of 2607 - ACR Meeting Abstracts

Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
Abstract Number: PP11 • ACR Convergence 2024
Living Well with Chronic Illness: Decades with MCTD
Carol KAMINSKI, HP (Hewlett Packard) Retired, Wilmington, NC
Background/Purpose: In the fall of 1985, I was not feeling well. I attributed my tiredness, weakness and malaise to stress and carried on. Walking upstairs I…
Abstract Number: PP02 • ACR Convergence 2024
Living Well with a Rare Rheumatic Disease – Becoming a “Precision” Patient on the Horizon of Precision Medicine
Ida Hakkarinen, self, Greenbelt, MD
Background/Purpose: My journey with a rare, chronic, relapsing rheumatic disease began in November 2010 with a variety of seemingly unrelated symptoms: migrating joint pain, night…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 2637 • ACR Convergence 2024
Chaperone-mediated Autophagy in Synovitis Distinguishes Psoriatic Arthritis from Rheumatoid Arthritis
Vincenzo Venerito¹, Gerardo Cazzato², Fabio Cacciapaglia³, Eleonora Ceglie⁴, Sergio Del Vescovo⁴, Teresa Caferri⁴, Giuseppe Lopalco⁴, Francesco Girolamo⁵ and Florenzo Iannone¹, ¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²Pathology Unit - University of Bari "Aldo Moro", IT, Bari, Italy, ³Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁴Rheumatology Unit - University of Bari "Aldo Moro", IT, Bari, Italy, ⁵Human Anatomy Department - University of Bari "Aldo Moro", IT, Bari, Italy
Background/Purpose: Recent studies have suggested that autophagy may play different roles in the pathogenesis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Lysosome-associated membrane protein type 2A…
Abstract Number: 2584 • ACR Convergence 2024
Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
Philip Mease¹, Alan Kivitz², Elena Muensterman³, Apinya Lertratanakul⁴, Ting Hong⁴, Jingjing Chen⁴, Ejim Mark⁵ and Xenofon Baraliakos⁶, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Takeda Development Center Americas, Cambridge, MA, ⁴Takeda Development Center Americas, Inc., Cambridge, MA, ⁵Takeda Development Center Americas Inc., Cambridge, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Zasocitinib (TAK-279) is an oral, selective TYK2 inhibitor under investigation for the treatment of immune-mediated inflammatory diseases including psoriatic arthritis (PsA). In a phase…
Abstract Number: 2683 • ACR Convergence 2024
Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries
Pavel Nikitin¹, Harshdeep Chawla¹, Manmohan Singh¹, Samuel Theodore², Salavat Aglyamov¹, Meng Zhang², Brian Skaug², Maureen Mayes², Kirill Larin¹ and Shervin Assassi², ¹University of Houston, Houston, TX, ²UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Vascular involvement is a prominent feature of systemic sclerosis (SSc). Safe and non-invasive methods to visualize cutaneous blood vessels beyond nailfold capillaries are lacking.…
Abstract Number: 2478 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Christian Pagnoux¹, Antoine Neel², Sarah Bray³, Rachel E. Gurlin⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Internal Medicine, CHU Nantes, Nantes, France, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
Abstract Number: 2595 • ACR Convergence 2024
TGF-β Activated Kinase 1 (TAK1) Inhibition Suppresses Synovial Inflammation and Tissue Destruction Mediated by Activated Juvenile Idiopathic Arthritis Synovial Fibroblasts
Meena Afroze Shanta¹, Paul Panipinto², Anil Singh³, Peter Nigrovic⁴, Lauren Henderson⁵ and Salahuddin Ahmed³, ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, ³Washington State university, Spokane, WA, ⁴Boston Children's Hospital, Brookline, MA, ⁵Boston Children's Hospital, Watertown, MA
Background/Purpose: Synovial inflammation is a common manifestation of juvenile idiopathic arthritis (JIA), often accompanied by debilitating synovial hyperplasia. The current study aims to characterize the…
Abstract Number: 2573 • ACR Convergence 2024
Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (COSPIRIT-JIA): 16-week Results of a Multicentre, Randomised, Open-label Study
Athimalaipet Ramanan¹, Nicolino Ruperto², Ivan Foeldvari³, Gabriel Vega Cornejo⁴, Stuart Keller⁵, Rona Wang⁵, Joana Araújo⁵, Maja Hojnik⁶, Priyanka Sen⁵, Ketan Marulkar⁵ and PIERRE QUARTIER⁷, ¹Bristol Royal Hosp for Children, Bristol, United Kingdom, ²IRCCS Giannina Gaslini, Genova, Italy, ³Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁴CREA de Guadalajara SC., Guadalajara, Mexico, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Co., Indianapolis, IN, ⁷Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France
Background/Purpose: Juvenile psoriatic arthritis (JPsA) and enthesitis-related-arthritis (ERA) are 2 categories of Juvenile Idiopathic Arthritis (JIA) according to the International League of Associations for Rheumatology…
Abstract Number: 2614 • ACR Convergence 2024
Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Ana Milena Gil¹, Julián Barahona-Correa², Jorge Bruce Flórez-Suárez³, Daniel Fernández-Ávila⁴ and Zulma Cucunubá¹, ¹Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia, ²Division of Rheumatology, Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, Colombia, ³Department of Immunology, Universidad Nacional de Colombia, Bogotá, Colombia, ⁴5Hospital San Ignacio, Colombia, BOGOTA, Colombia
Background/Purpose: The association between SARS-CoV-2 infection and the new onset of immune-mediated diseases is a topic of interest given the conflicting evidence available. This systematic…
Abstract Number: 2648 • ACR Convergence 2024
Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging
Vicente Aldasoro¹, Vicky Betech-Antar², Santos Castañeda³, Eugenio De Miguel⁴, Juan José Rosales⁵ and Maria Jose García Velloso⁵, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Clinica Universidad de Navarra, Pamplona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Clínica Universidad de Navarra, Pamplona, Spain
Background/Purpose: The aim of this study is to analyse the diagnostic value of the delay images at 180 minutes in positron emission tomography (PET) performed in…
Abstract Number: 2498 • ACR Convergence 2024
The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis
Veronica Pulito-Cueto¹, Joao Carlos Batista-Liz¹, Laura Carmen Terron², Iván Fernández Rengel³, María Sebastián Mora-Gil⁴, María Teresa Leonardo⁵, Ana Peñalba⁵, Luis Martín-Penagos⁶, Lara Belmar-Vega⁷, Cristina Gomez-Fernandez⁸, Ligia Gabrie-Rodriguez⁹, Rafael Gálvez Sánchez⁹, Luis Caminal-Montero¹⁰, Ana Turrion Nieves¹¹, Patricia Quiroga Colina¹², Esther Vicente-rabaneda¹³, Belén Sevilla-Pérez¹⁴, José Luis Callejas¹⁵, Eduardo Andrés-León², Javier Martin¹⁶, Ana María Marquez¹⁷, Santos Castañeda¹³, Ricardo Blanco-Alonso¹⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Unidad de Bioinformática, Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Granada, Spain, ³Bioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, GENYO, Cen, Granada, Spain, ⁴Immunopathology Group, IDIVAL, Santander, Spain, ⁵Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, ⁸Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ¹¹Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁵Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁶Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ¹⁷Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Nephritis is the main cause of long-term morbidity and mortality in patients with Immunoglobulin-A vasculitis (IgAV) [1, 2]. Unfortunately, sensitive, specific, and non-invasive biomarkers…
Abstract Number: 2625 • ACR Convergence 2024
Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus
Oscar Mwizerwa¹, Justine Ledochowski², Tala El Tal³, Ganesh Ramanathan², Sarah Mossad⁴, Ibrahim Mohamed⁵, Joanna Law⁶, Lawrence Ng², Paris Moaf², Asha Jeyanathan¹, Adrienne Davis⁷, Ann Yeh², Linda Hiraki², Deborah Levy², Zahi Touma⁸, Joan Wither⁹, Busi Zapparoli¹⁰, Ashley Danguecan¹¹ and Andrea Knight¹², ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Brampton, ON, Canada, ⁶The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Etobicoke, ON, Canada, ¹¹The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ¹²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) commonly experience impaired executive function (EF), and attribution to neuropsychiatric lupus (NPSLE) is challenging. Serum markers of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].